Company invests in DeSci blockchain innovation and purchases native coin of ResearchHub, a decentralized science platform co-founded by Coinbase CEO, Brian Armstrong SARASOTA, FL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchase of ResearchCoin (RSC) as part of its expanded digital assets treasury strategy designed to capture long-term va ...

SARASOTA, FL, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share. In a c ...

SARASOTA, FL, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into definitive agreements for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share in a registered direct offering priced at-the-market under Nasdaq ...

Fireblocks is a globally recognized leader in the digital assets space, facilitating the secure transfer of more than $10 trillion to date SARASOTA, FL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, announced that it has begun implementing its strategic agreement with Fireblocks, an enterprise platform for secure digital asset custody, settlement, trading operations, and s ...

Silo Wellness Submits CSE Listing Statement for Review of Born Defense Proposed Change of BusinessSeptember 28, 2025 5:47 PM EDT | Source: Silo Wellness Inc.Eugene, Oregon and Toronto, Ontario--(Newsfile Corp. - September 28, 2025) - Silo Wellness Inc. (CSE: SILO) ("Silo" or the "Company"), to be renamed Born Defense Inc., is pleased to announce that it has submitted its listing statement (the "Listing Statement") with the Canadian Securities Exchange (the "CSE") on September 26, 2025, for rev ...

Highly secure, institutional-grade infrastructure supports Bitcoin, Ethereum and Solana treasury strategySARASOTA, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that it has engaged Fireblocks, an enterprise platform for building blockchain applications and managing digital asset operations, as custodian for its institutional crypto treasury platform. “O ...

Silo Pharma Inc. (NASDAQ:SILO) on Wednesday announced that it has engaged Fireblocks, an enterprise platform for building blockchain applications and managing digital asset operations, as custodian for its institutional crypto treasury platform. "Our engagement with Fireblocks is expected to ensure that our newly deployed crypto treasury platform is built with enterprise-grade security and governance standards," said Silo CEO Eric Weisblum. Fireblocks is a platform in the digital assets space, having fa ...

公司战略举措 - 公司启动加密货币国库策略 首次购买以太坊(ETH)和Solana(SOL)代币作为多链资产增长目标的首步实施 [1][2] - 通过质押代币实现收益生成和资本增值 旨在强化财务状况并支持生物制药资产的临床进展 [3] - 数字资产战略与机构投资者及全球企业加速采用趋势保持一致 监管环境持续演进推动更广泛市场接受度 [3] 业务发展重点 - 公司定位为多元化发展阶段生物制药与加密货币国库企业 治疗领域聚焦服务不足的应激性精神障碍/慢性疼痛及中枢神经系统疾病 [4] - 产品组合包含创新项目：SPC-15针对创伤后应激障碍 SP-26针对纤维肌痛和慢性疼痛 以及针对阿尔茨海默病和多发性硬化症的临床前资产 [4] - 研究合作网络涵盖顶尖大学和实验室 通过协同研发推进管线进展 [4] 技术整合方向 - 首次代币收购为区块链国库模型奠定基础 支持更广泛的现实世界资产(RWA)代币化计划推进 [2] - 公司坚信去中心化区块链与去中心化金融作为领先智能合约平台的长期价值 认为底层技术将塑造生物技术未来 [2][3]

公司产品发布 - Saucony SILO AW25系列将于2025年9月18日全球上市 包含全新鞋型和对经典款式的升级迭代 [1][3] - 新系列推出两款全新鞋型：MomentumS（致敬品牌步行鞋传统 采用专利皮革与网眼双色鞋面）和TrekkerS（越野灵感设计 配备Vibram Megagrip外底） [5] - 同时更新GridXUltraS、GripperS、586iS和Kinvara1S等经典款式的配色方案与外观设计 [5] 产品设计理念 - 创意总监Paul Ruffles强调AW25系列通过文化驱动设计视角重构品牌遗产 实现档案设计与性能设计的共存 [2] - 首席产品官Brian Moore指出新系列精准平衡传统、材料创新与形态 从鞋底技术到表面处理均追求极致 [3] - 系列延续"纯粹形态"概念第二阶段 与布景设计师、造型师和编舞师合作 通过运动与叙事重新诠释设计哲学 [2] 品牌战略定位 - Saucony为全球性能跑鞋与生活方式品牌 隶属上市公司Wolverine World Wide Inc (NYSE: WWW) [4] - SILO系列定位高端市场 融合传统、奢华与性能 于2025年6月巴黎时装周首次亮相 [1] - 品牌拥有PWRRUN PB、PWRRUN+和SPEEDROLL等获奖技术 覆盖路跑、越野与原创产品线 [4] 销售渠道与历史 - 产品将通过全球精选零售商及官方电商平台sauconysilo.com销售 [3] - 品牌成立于1898年 以跑步文化推动生活方式变革为核心使命 [4] - 此前SS25系列"纯粹形态第一部"已于2025年4月全球发布 [2]

公司专利与知识产权进展 - 日本专利局向哥伦比亚大学授予专利号7683882 涉及血清素4受体激动剂在应激预防中的功效 该专利由Silo Pharma独家授权[1] - 该专利强化了公司核心资产SPC-15的保护 SPC-15为鼻内给药治疗创伤后应激障碍(PTSD)的候选药物[2] - 公司首席执行官表示日本专利为国际知识产权组合增加保护层 专利库扩展构成新型PTSD疗法开发及监管策略的基石[2] 核心资产SPC-15特性 - SPC-15为靶向血清素5-HT4受体的鼻内激动剂 用于治疗应激诱导的精神障碍包括PTSD和焦虑症[2] - 符合FDA 505(b)(2)简化监管路径资格 可能加速审批流程[2] - 正与哥伦比亚大学开展临床前研究 公司拥有SPC-15的全球独家开发和商业化权利[2] 公司业务与研发管线 - 公司为多元化发展阶段的生物制药与加密货币库企业 专注于未满足医疗需求的领域[3] - 治疗领域涵盖应激诱导的精神障碍、慢性疼痛及中枢神经系统疾病[3] - 研发管线包括针对纤维肌痛和慢性疼痛的SP-26 以及针对阿尔茨海默病和多发性硬化的临床前资产[3] - 研发模式为与顶尖大学及实验室合作推进[3]